Therapeutic-antagonists of oestrogens can be produced for cancer and other therapies using cytochromes P450 (CYP).
Oestrogens such as 17beta-oestradiol initiates nuclear-gene transcription in gender-specified tissues such as the ovaries and mammaries; and unfortunately too in cancer cells derived from target tissues. Consequently, there has been the development of novel agents for particular cancer therapies that are antagonists of oestrogens for oestrogen-receptor (ER) binding and of drugs with ER-specific interference RNA (RNAi) abilities. Therapeutic-antagonists of oestrogens will be re-designed and biosynthesised and deployed to circumvent the gene DNA-transcription abilities of oestrogens and mimics: and their metabolites in oestrogen-target tissues (see above). Furthermore, opportunities will emerge for adjunct-chemotherapy of particular tissue cancers: and in the prevention of recurrence outcomes. Cytochromes P450 can play an important part in these developments especially for the production of novel metabolites of oestrogens as therapeutic-antagonists of oestrogen-stimulated cancers.
Wiseman
Alan
A
School of Biomedical and Molecular Sciences, University of Surrey, Guildford GU2 7XH, UK. alan@tridgway.wanadoo.co.uk
D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D003577:Cytochrome P-450 Enzyme System / Q000627:therapeutic use*; D015195:Drug Design; D004965:Estrogen Antagonists / Q000627:therapeutic use*; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy*; D011960:Receptors, Estrogen / Q000037:antagonists & inhibitors
D000970:Antineoplastic Agents; D004965:Estrogen Antagonists; D011960:Receptors, Estrogen; D003577:Cytochrome P-450 Enzyme System